Pharma major

制药巨头

Lupin

鲁邦三世

Ltd on Monday said it has signed a license and supply agreement with China's

有限公司周一表示，已与中国签署了许可和供应协议

Sino Universal Pharmaceuticals

中国环球制药

for the commercialisation of

用于商业化

Tiotropium dry powder inhaler

噻托溴铵干粉吸入剂

in the Chinese market.

在中国市场。

The agreement pertains to the commercialisation of the Tiotropium dry powder inhaler of strength 18 mcg/capsule, which is used in the treatment of

该协议涉及用于治疗的18微克/胶囊的噻托溴铵干粉吸入剂的商业化，

Chronic Obstructive Pulmonary Disease

慢性阻塞性肺疾病

(COPD),

慢性阻塞性肺疾病（COPD），

Lupin

鲁邦三世

said in a regulatory filing.

在监管文件中表示。

Under the agreement, Sino Universal Pharmaceuticals (SUP) will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorisation holder and responsible for manufacturing of the product, it added.

根据协议，中国环球制药（SUP）将获得在中国销售噻托溴铵干粉吸入剂的监管批准，而卢平将作为上市许可持有人并负责产品的生产。

'This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global

“这一合作表明了我们致力于开发治疗慢性阻塞性肺病等呼吸系统疾病的关键产品，并确立我们在全球的领导地位。

respiratory health

呼吸健康

sector,' Lupin President Corporate Development, Fabrice Egros said.

部门，’卢平公司企业发展总裁法布里斯·埃格罗斯说。

With SUP, the company aim to enhance patient access to innovative and high-quality

通过SUP，公司旨在提高患者获得创新和高质量的机会

healthcare solutions

医疗解决方案

, Egros added.

，埃格罗斯补充道。

Live Events

现场活动

Commenting on the partnership, SUP President Wang Li said, 'Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care.' .

苏州弘森药业股份有限公司总裁王莉在谈到此次合作时表示：“Lupin在呼吸系统疾病治疗领域的深厚承诺及其以创新为导向的高品质产品战略与苏州弘森的战略愿景完全契合。我们相信，这次合作将加强我们在呼吸护理方面的协同效应。”

By bringing more efficient and superior products to market, Li said, 'We aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health.'

李说，通过将更高效和优质的产品推向市场，“我们旨在在中国的呼吸系统疾病治疗方面取得重大突破，让更多患者受益于国际高品质和创新产品，享受呼吸健康。”

Lupin said the partnership will enable it to expand its footprint in China.

Lupin表示，该合作将使其能够扩大在中国的业务范围。

Tiotropium dry powder inhaler is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions, Lupin said. PTI

卢平表示，噻托溴铵干粉吸入器在改善呼吸系统疾病患者的肺功能和生活质量方面具有显著疗效。

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)